Thrombin generation capacity is enhanced by low antithrombin activity and depends on the activity of the related coagulation factors

Abstract

Background Supplementation with antithrombin (AT) concentrates is now common in the treatment of congenital and acquired AT deficiency. However, there is no established consensus on the target and timing of supplementation. We aimed to elucidate the effects of AT deficiency on the balance between coagulation activation and inhibition using a thrombin generation assay as in vitro global assay. Methods Samples were prepared by admixing commercially acquired AT-deficient plasma with < 1% AT activity with pooled normal plasma. The AT activity in each sample was adjusted to 100, 90, 70, 50, 40, 30, 10, 5, and < 1%. A thrombin generation assay was performed in each sample. AT concentrate-spiked samples were also prepared by adjusting the AT activities in four types of the concentrates: one recombinant and three plasma-derived AT concentrates. The final targeted AT activities in the samples were adjusted to 100, 50, 30, and 5% by spiking each concentrate into the AT-deficient plasma. We also prepared samples with five levels of prothrombin time (PT) % in coagulation factors with the AT activity fixed at 30% by dilution by mixing AT-deficient plasma and normal plasma with Owren’s veronal buffer to adjust the coagulation factor activities in several proportions. The theoretical target PT% values were 100, 66, 50, 40, and 30%. A thrombin generation assay was performed on all samples. Results The ability to generate thrombin depended on the AT activity, and the amount of thrombin generation was increased as AT was decreased. Additionally, the amount of thrombin generation was changed significantly when AT activity was ≤ 50%, indicating that AT suppressed thrombin generation. In particular, thrombin generation was remarkable when AT activity was < 30%, and it can be assumed that the prognosis is poor due to organ failure from thrombotic tendency. Conclusions The results presented in this basic research were found to be consistent with the clinical findings to date. The mechanism by which 30–50% of AT activity is set as the clinical boundary was elucidated by the thrombin generation assay.

Active antithrombin glycoforms are selectively physiosorbed on plasma extracellular vesicles

“…Finally, we plotted a calibration line (Figure 3b, blue dots) and used it to estimate the amount of AT contained in the EV sample (Figure 3b, red star). The plotted value of each standard corresponds to the mean plasma AT content calculated from the maximum and the minimum plasma AT content reported in literature (Tsuchida et al, 2022). From our calculations, it appears that the amount of AT physiosorbed  of  F I G U R E  Semi-quantitative analysis of AT concentration on EVs.…”

Risk stratification utilizing sequential organ failure assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC)

“…A major goal of this current study was to find an appropriate target value for initiating antithrombin therapy. Using acquired antithrombin-deficient plasma, Tsuchida et al 20 demonstrated thrombin generation capability depends on the antithrombin activity. The study demonstrated that the amount of thrombin generation exhibited significant changes when antithrombin activity reached 50% or lower, with particularly notable generation observed when antithrombin activity dropped below 30%.…”

Limb Ischemic Necrosis Secondary to Microvascular Thrombosis: A Brief Historical Review

“…It is surprising to many clinicians that limb ischemic necrosis can result from thrombosis that only involves veins. Although reports on venous gangrene date from over 150 years ago (e.g., 49,50 Natural anticoagulant reference ranges shown are usual adult ranges. Concentrations given in U/mL are synonymous with the designation IU/mL (per the SI system).…”